Compumedics Hires Medtech Veteran Mike Stone to Lead US Commercial Expansion

Compumedics has appointed Mike Stone as Chief Commercial Officer for its US operations, a strategic move to accelerate commercial penetration in the company’s largest addressable market. Stone brings over 20 years of medical device commercial leadership experience, including management of a $500M+ P&L at Smiths Medical, and has already begun strengthening the US team with several high-calibre hires since joining.

Compumedics bolsters US commercial firepower with veteran medtech executive

The appointment positions Stone to execute a two-pronged mandate: building out Compumedics’ US neurodiagnostics business and strengthening the sleep and IDTF (Independent Diagnostic Testing Facility) commercial teams. This includes driving commercial expansion for Somfit, the company’s EEG-enabled home sleep testing platform that Stone described as “exceptionally well positioned for where the HST market and reimbursement landscape are heading.”

The hire signals Compumedics is prioritising revenue scaling infrastructure rather than simply filling an organisational vacancy. Stone has already made several high-calibre appointments to the US team, with additional key hires underway. The timing aligns with the company’s broader push to convert differentiated technology into measurable US market traction.

Investment significance: Commercial execution is the bottleneck for many medtech companies with strong products. This appointment signals Compumedics is prioritising revenue scaling infrastructure in its largest addressable market.

Who is Mike Stone?

Stone’s career trajectory establishes direct domain credibility in the channels Compumedics targets:

• Nihon Kohden (Vice President of Sales, Neurology): Transformed an underperforming business and delivered strong double-digit growth sustained over multiple years. Direct domain experience in EEG, sleep diagnostics, and software sales.
• Smiths Medical (Vice President of Sales): Managed a $500M+ P&L and held the commercial organisation together through its acquisition by ICU Medical, demonstrating talent retention through M&A transitions.
• Henry Schein (post-acquisition integration): Led commercial team building across multiple transactions at the Fortune 250 healthcare products and distribution leader.
• Baxter International (Commercial Operations): Led operations spanning alternate site distribution and pharmaceutical manufacturing channels.

Stone holds an MBA from Georgia State University and a BS from the University of South Florida. He is based in Wellington, Florida.

Investment significance: Stone’s direct experience in EEG, sleep diagnostics, and neurology sales, combined with his track record of retaining talent through M&A transitions, addresses two key investor concerns: domain expertise and execution risk during scale-up.

What is a Chief Commercial Officer and why does this role matter?

A Chief Commercial Officer typically owns revenue generation, sales strategy, commercial team structure, and customer relationships. For medical device companies, this role carries particular weight due to the complexity of hospital procurement processes, extended sales cycles, reimbursement navigation, and post-acquisition integration challenges.

The CCO role becomes especially critical when a company has differentiated products but lacks the commercial reach to convert technical advantage into revenue growth. Compumedics has built three core commercial assets: Somfit (EEG-enabled home sleep testing), a world-class neuro hardware line, and Nexus 360 (the software platform connecting the product ecosystem). Stone’s mandate is to translate this product strength into measurable US market penetration.

Investment significance: Product-market fit without commercial execution leaves value on the table. The CCO role is the bridge between R&D capability and revenue realisation.

Strategic priorities: neurodiagnostics and sleep expansion

Stone’s remit encompasses two parallel growth tracks: expanding Compumedics’ US neurodiagnostics business and strengthening the sleep and IDTF commercial teams. Somfit, the company’s EEG-enabled home sleep testing platform, sits at the centre of the commercial strategy.

Stone’s assessment of the Somfit opportunity is particularly relevant for investors tracking reimbursement tailwinds in home sleep testing. The platform combines EEG capability with home-based deployment, positioning it to capture both clinical demand and payer preference for lower-cost diagnostic pathways.

Mike Stone, Chief Commercial Officer, Compumedics USA

“Compumedics has built something genuinely differentiated — an EEG-enabled home sleep platform in Somfit, a world-class neuro hardware line, and Nexus 360 to tie it together. Somfit is exceptionally well positioned for where the HST market and reimbursement landscape are heading. The priority now is expanding our commercial reach, serving more patients and providers across the US, and driving meaningful growth. I’m looking forward to engaging with current and future customers at SLEEP 2026 in Baltimore later this month as we continue to build momentum in the market.”

The upcoming SLEEP 2026 conference in Baltimore later this month represents an immediate commercial engagement opportunity. Stone confirmed the company will use the event to engage with current and future customers, providing investors with a near-term visibility point on commercial momentum.

Executive Chairman’s perspective

Dr. David Burton, Executive Chairman, framed the appointment as evidence of strategic timing rather than reactive hiring. His commentary positions Stone as the appropriate commercial leader for Compumedics’ current growth stage.

Dr. David Burton, Executive Chairman

“Mike brings exactly the commercial depth and leadership experience we need at this stage of our US growth. His track record of scaling teams, leading organisations through significant transitions, and driving results across neurodiagnostics and sleep makes him the right person to lead this next chapter for Compumedics in the US.”

What this means for CMP shareholders

The appointment represents a capability upgrade in the company’s weakest historical link: US commercial scale. Compumedics has built differentiated technology across sleep diagnostics and neurodiagnostics. The investment question has been execution rather than product merit.

Stone’s immediate momentum, hiring several team members since joining with more appointments underway, signals this is an operational priority rather than a box-ticking exercise. The SLEEP 2026 conference in Baltimore provides a near-term catalyst for investor visibility on commercial progress.

Compumedics’ commercial momentum extends beyond the US market, with MEG system orders totalling approximately $30 million contracted and revenue recognition running through FY27, providing a separate but complementary growth track to the domestic sleep and neurodiagnostics expansion Stone is now leading.

Investment significance: The appointment represents a capability upgrade in the company’s weakest historical link (US commercial scale). Investors should watch for sales team expansion updates and SLEEP 2026 conference outcomes as progress markers.

Want the Next MedTech Breakthrough in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get healthcare sector updates the moment they hit the market.